EE274 Is It Worthwhile for an Orphan Product to Expand Indications Given the Risk of Medicare Negotiation?
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.575
https://www.valueinhealthjournal.com/article/S1098-3015(23)00675-7/fulltext
Title :
EE274 Is It Worthwhile for an Orphan Product to Expand Indications Given the Risk of Medicare Negotiation?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00675-7&doi=10.1016/j.jval.2023.03.575
First page :
Section Title :
Open access? :
No
Section Order :
10057